Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Astellas Pharma Inc. ("Astellas"; headquarters: Tokyo; President and CEO: Toichi Takenaka) has obtained marketing approval for its overactive bladder treatment Vesicare (YM905) with the indication...
Astellas Pharma Inc. ("Astellas"; headquarters: Tokyo; President and CEO: Toichi Takenaka) has today announced that the candin antifungal agent, "Funguard® for Infusion" (generic name: micafungin...
Read more about Approval for Candin Antifungal Agent Funguard for Pediatrics in Japan
Tokyo, Japan April 17, 2006 - Astellas Pharma Inc. (President and CEO: Toichi Takenaka, "Astellas") today announced that the total consideration for the sale of all outstanding shares of Zepharma...
Read more about Consideration of the sale of Zepharma shares has been fixed
Japan, April 13, 2006 - Astellas Pharma Inc. ("Astellas"; headquarters: Tokyo; President and CEO: Toichi Takenaka) has today announced that its EU subsidiary submitted a Marketing Authorization...
Read more about MAA Submission for Candin Antifungal Agent Micafungin in EU
Astellas Pharma Inc.("Astellas"; headquarters: Tokyo; President and CEO: Toichi Takenaka) announced that Astellas today established a new active pharmaceutical ingredient (API) manufacturing...
Read more about Astellas Establishes New Subsidiary "Astellas Pharma Chemicals Co., Ltd."
Follow us
